Dr Monica Patel

2025

Chapter in Book - Research

Ehrlich, B., Patel, M., Zheng, X., & Glass, M. (2025). Canonical cannabinoid receptors. In Current topics in behavioral neurosciences. Berlin, Germany: Springer. doi: 10.1007/7854_2024_556

2024

Journal - Research Article

Patel, M., Zheng, X., Akinfiresoye, L. R., Prioleau, C., Walker, T. D., Glass, M., & Marusich, J. A. (2024). Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists. European Journal of Pharmacology, 971, 176549. doi: 10.1016/j.ejphar.2024.176549

Ryalls, B., Patel, M., Sparkes, E., Banister, S. D., Finlay, D. B., & Glass, M. (2024). Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB₁ receptor. Biochemical Pharmacology, 222, 116052. doi: 10.1016/j.bcp.2024.116052

2023

Journal - Research Article

Patel, M., Grimsey, N. L., Banister, S. D., Finlay, D. B., & Glass, M. (2023). Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB₂ receptor. Pharmacology Research & Perspectives, 11, e01157. doi: 10.1002/prp2.1157

Awarded Doctoral Degree

Patel, M. (2023). Molecular pharmacology of synthetic cannabinoid receptor agonists. Exploring potential mechanisms underpinning synthetic cannabinoid receptor agonist toxicity beyond activity at the cannabinoid CB1 receptor (PhD). University of Otago, Dunedin, New Zealand. Retrieved from http://hdl.handle.net/10523/16427

2022

Conference Contribution - Verbal presentation and other Conference outputs

Ehrlich, B. E., Patel, M., Banister, S. D., Finlay, D. B., & Glass, M. (2022, August-September). Investigating G protein vs β-arrestin bias of late-generation synthetic cannabinoids at the CB1 receptor. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

Patel, M., Matti, C., Grimsey, N. L., Legler, D. F., Finlay, D. B., & Glass, M. (2022, August-September). Delineating the interactions between the cannabinoid CB₂ receptor and its regulatory effectors: β-arrestin 2 and G protein-coupled receptor kinases. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

2021

Journal - Research Article

Patel, M., Matti, C., Grimsey, N. L., Legler, D. F., Javitch, J. A., Finlay, D. B., & Glass, M. (2021). Delineating the interactions between the cannabinoid CB₂ receptor and its regulatory effectors: β‐arrestins and GPCR kinases. British Journal of Pharmacology, 179, 2223-2239. doi: 10.1111/bph.15748

Patel, M., Finlay, D. B., & Glass, M. (2021). Biased agonism at the cannabinoid receptors: Evidence from synthetic cannabinoid receptor agonists. Cellular Signaling, 78, 109865. doi: 10.1016/j.cellsig.2020.109865

Conference Contribution - Published proceedings: Abstract

Khalajiassadi, N., Finlay, D., Patel, M., & Glass, M. (2021). ABM300, a new negative allosteric modulator of the CB₁ cannabinoid receptor, exhibits a similar mechanism of action as ORG27569. New Zealand Medical Journal, 134(1537), (pp. 117). Retrieved from https://www.nzma.org.nz/journal

2020

Journal - Research Article

Patel, M., Manning, J. J., Finlay, D. B., Javitch, J. A., Banister, S. D., Grimsey, N. L., & Glass, M. (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 175, 113871. doi: 10.1016/j.bcp.2020.113871

2019

Journal - Research Article

Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429

Ibsen, M. S., Finlay, D. B., Patel, M., Javtich, J. A., Glass, M., & Grimsey, N. L. (2019). Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: Species, subtype, and agonist-dependence. Frontiers in Pharmacology, 10, 350. doi: 10.3389/fphar.2019.00350

Conference Contribution - Published proceedings: Abstract

Sachdev, S., Santiago, M., Patel, M., Manandhar, P., Udoh, M., Glass, M., & Connor, M. (2019). Investigation of the specificity of cannabidiol signalling. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 52). Retrieved from https://www.asceptasm.com

Conference Contribution - Poster Presentation (not in published proceedings)

Patel, M., Manning, J. J., Finlay, D. B., Banister, S. D., Grimsey, N. L., & Glass, M. (2019, August-September). Novel synthetic cannabinoids possess signalling profiles distinct from THC at the type 1 cannabinoid receptor. Poster session presented at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.